Cargando…

Breast cancer risk-assessment models

There are two main questions when assessing a woman for interventions to reduce her risks of developing or dying from breast cancer, the answers of which will determine her access: What are her chances of carrying a mutation in a high-risk gene such as BRCA1 or BRCA2? What are her risks of developin...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, D Gareth R, Howell, Anthony
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2242652/
https://www.ncbi.nlm.nih.gov/pubmed/17888188
http://dx.doi.org/10.1186/bcr1750
_version_ 1782150560556777472
author Evans, D Gareth R
Howell, Anthony
author_facet Evans, D Gareth R
Howell, Anthony
author_sort Evans, D Gareth R
collection PubMed
description There are two main questions when assessing a woman for interventions to reduce her risks of developing or dying from breast cancer, the answers of which will determine her access: What are her chances of carrying a mutation in a high-risk gene such as BRCA1 or BRCA2? What are her risks of developing breast cancer with or without such a mutation? These risks taken together with the risks and benefits of the intervention will then determine whether an intervention is appropriate. A number of models have been developed for assessing these risks with varying degrees of validation. With further improvements in our knowledge of how to integrate risk factors and to eventually integrate further genetic variants into these models, we are confident we will be able to discriminate with far greater accuracy which women are most likely to develop breast cancer.
format Text
id pubmed-2242652
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22426522008-02-14 Breast cancer risk-assessment models Evans, D Gareth R Howell, Anthony Breast Cancer Res Review There are two main questions when assessing a woman for interventions to reduce her risks of developing or dying from breast cancer, the answers of which will determine her access: What are her chances of carrying a mutation in a high-risk gene such as BRCA1 or BRCA2? What are her risks of developing breast cancer with or without such a mutation? These risks taken together with the risks and benefits of the intervention will then determine whether an intervention is appropriate. A number of models have been developed for assessing these risks with varying degrees of validation. With further improvements in our knowledge of how to integrate risk factors and to eventually integrate further genetic variants into these models, we are confident we will be able to discriminate with far greater accuracy which women are most likely to develop breast cancer. BioMed Central 2007 2007-09-12 /pmc/articles/PMC2242652/ /pubmed/17888188 http://dx.doi.org/10.1186/bcr1750 Text en Copyright © 2007 BioMed Central Ltd
spellingShingle Review
Evans, D Gareth R
Howell, Anthony
Breast cancer risk-assessment models
title Breast cancer risk-assessment models
title_full Breast cancer risk-assessment models
title_fullStr Breast cancer risk-assessment models
title_full_unstemmed Breast cancer risk-assessment models
title_short Breast cancer risk-assessment models
title_sort breast cancer risk-assessment models
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2242652/
https://www.ncbi.nlm.nih.gov/pubmed/17888188
http://dx.doi.org/10.1186/bcr1750
work_keys_str_mv AT evansdgarethr breastcancerriskassessmentmodels
AT howellanthony breastcancerriskassessmentmodels